Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00429091 · ClinicalTrials.gov registry record · Phase 2
A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 2
- Development phase
- 243
- Enrollment target
NCT00429091 is a Phase 2 study that has completed, run by Abbott. The registered enrollment target is 243 participants.
The verdict
NCT00429091, a Phase 2 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 243 participants
- Enrollment target
Study Summary
A Dose-Ranging Study of the Efficacy of ABT-894 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
- DRUG placebo
- DRUG atomoxetine
- DRUG ABT-894
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00429091
The ClinicalTrials.gov registry entry for NCT00429091 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00429091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00429091 about?
NCT00429091 is a clinical study titled "A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)". A Dose-Ranging Study of the Efficacy of ABT-894 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
What is the current status of trial NCT00429091?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 243 participants. The study started on 2007-01.
What interventions are being tested in trial NCT00429091?
The interventions under investigation include: placebo (DRUG), atomoxetine (DRUG), ABT-894 (DRUG).
Who is sponsoring clinical trial NCT00429091?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.